Lv2
200 积分 2021-01-03 加入
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
9天前
已完结
Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease
6个月前
已完结
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial
7个月前
已完结
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT
7个月前
已完结
Rituximab for posttransplant lymphoproliferative disorder – therapeutic, preemptive, or prophylactic?
8个月前
已完结
Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203
8个月前
已完结
Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study
9个月前
已完结
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia
10个月前
已完结
Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation
11个月前
已关闭
Approaching a therapeutic inflection point for FLT3-mutated AML
11个月前
已关闭
皖公网安备34019202002308
